- Home
- ZBIO vs UPB Comparison
ZBIO vs UPB Comparison
Compare ZBIO & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- UPB
- Stock Information
- Founded
- ZBIO 2019
- UPB 2021
- Country
- ZBIO United States
- UPB United States
- Employees
- ZBIO N/A
- UPB N/A
- Industry
- ZBIO
- UPB
- Sector
- ZBIO
- UPB
- Exchange
- ZBIO NYSE
- UPB NYSE
- Market Cap
- ZBIO 389.2M
- UPB 521.3M
- IPO Year
- ZBIO 2024
- UPB 2024
- Fundamental
- Price
- ZBIO $10.41
- UPB $11.15
- Analyst Decision
- ZBIO Strong Buy
- UPB Strong Buy
- Analyst Count
- ZBIO 7
- UPB 4
- Target Price
- ZBIO $32.29
- UPB $56.50
- AVG Volume (30 Days)
- ZBIO 221.4K
- UPB 504.0K
- Earning Date
- ZBIO 08-16-2025
- UPB 08-14-2025
- Dividend Yield
- ZBIO N/A
- UPB N/A
- EPS Growth
- ZBIO N/A
- UPB N/A
- EPS
- ZBIO N/A
- UPB N/A
- Revenue
- ZBIO $15,000,000.00
- UPB $2,296,000.00
- Revenue This Year
- ZBIO $206.00
- UPB N/A
- Revenue Next Year
- ZBIO $41.92
- UPB N/A
- P/E Ratio
- ZBIO N/A
- UPB N/A
- Revenue Growth
- ZBIO N/A
- UPB N/A
- 52 Week Low
- ZBIO $5.83
- UPB $5.14
- 52 Week High
- ZBIO $26.25
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- UPB N/A
- Support Level
- ZBIO N/A
- UPB N/A
- Resistance Level
- ZBIO N/A
- UPB N/A
- Average True Range (ATR)
- ZBIO 0.00
- UPB 0.00
- MACD
- ZBIO 0.00
- UPB 0.00
- Stochastic Oscillator
- ZBIO 0.00
- UPB 0.00
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.